It has exhibited considerable therapeutic efficacy in patients with RET fusion-positive metastatic NSCLC, RET mutant MTC, and RET fusion-positive thyroid, with no significant off-target toxicity [154,169]. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.